CN107205950B - 金刚烷胺组合物的施用方法 - Google Patents

金刚烷胺组合物的施用方法 Download PDF

Info

Publication number
CN107205950B
CN107205950B CN201580072014.7A CN201580072014A CN107205950B CN 107205950 B CN107205950 B CN 107205950B CN 201580072014 A CN201580072014 A CN 201580072014A CN 107205950 B CN107205950 B CN 107205950B
Authority
CN
China
Prior art keywords
amantadine
hours
composition
administered
administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201580072014.7A
Other languages
English (en)
Chinese (zh)
Other versions
CN107205950A (zh
Inventor
格雷戈里·T·文特
蒂莫西·J·富尔茨
杰克·源
戴维·切尔诺夫
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Adamas Pharmaceuticals Inc
Original Assignee
Adamas Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Adamas Pharmaceuticals Inc filed Critical Adamas Pharmaceuticals Inc
Publication of CN107205950A publication Critical patent/CN107205950A/zh
Application granted granted Critical
Publication of CN107205950B publication Critical patent/CN107205950B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN201580072014.7A 2014-11-04 2015-11-03 金刚烷胺组合物的施用方法 Active CN107205950B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462075137P 2014-11-04 2014-11-04
US62/075,137 2014-11-04
PCT/US2015/058872 WO2016073510A1 (en) 2014-11-04 2015-11-03 Methods of administering amantadine compositions

Publications (2)

Publication Number Publication Date
CN107205950A CN107205950A (zh) 2017-09-26
CN107205950B true CN107205950B (zh) 2021-06-04

Family

ID=55909712

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201580072014.7A Active CN107205950B (zh) 2014-11-04 2015-11-03 金刚烷胺组合物的施用方法

Country Status (14)

Country Link
US (1) US20160228388A1 (enExample)
EP (2) EP3215132B1 (enExample)
JP (1) JP6735020B2 (enExample)
CN (1) CN107205950B (enExample)
AU (1) AU2015343199B2 (enExample)
BR (1) BR112017009289A2 (enExample)
CA (1) CA2966195C (enExample)
ES (1) ES2865278T3 (enExample)
HU (1) HUE055779T2 (enExample)
MX (1) MX376782B (enExample)
PL (1) PL3215132T3 (enExample)
PT (1) PT3215132T (enExample)
SI (1) SI3215132T1 (enExample)
WO (1) WO2016073510A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014204933A1 (en) 2013-06-17 2014-12-24 Adamas Pharmaceuticals, Inc. Amantadine compositions and methods of use
IL272834B2 (en) 2017-08-24 2024-08-01 Adamas Pharma Llc Amantadine compositions, preparations thereof, and methods of use
TR201720406A2 (tr) 2017-12-14 2019-07-22 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Bi̇r i̇skelet kasi gevşeti̇ci̇si̇ ve bi̇r multi̇pl skleroz tedavi̇ edi̇ci̇ ajan i̇çeren kombi̇nasyonlar
WO2019245513A2 (en) 2018-06-21 2019-12-26 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi A combination comprising fingolimod and amantadine
TR201818307A2 (tr) * 2018-11-30 2020-06-22 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Di̇meti̇l fumarat i̇çeren bi̇r kompozi̇syon
TR201818859A2 (tr) 2018-12-07 2020-06-22 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Di̇meti̇l fumarat ve en az bi̇r kas gevşeti̇ci̇ ajan i̇çeren bi̇r kombi̇nasyon
TR201819202A2 (tr) 2018-12-12 2020-06-22 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Bi̇r multi̇pl skleroz ajani ve en az bi̇r kas relaksan ajan i̇çeren bi̇r kombi̇nasyon
TR201820976A2 (tr) 2018-12-28 2020-07-21 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Fi̇ngoli̇mod ve bi̇r spazmoli̇ti̇k i̇çeren farmasöti̇k kombi̇nasyonlar

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102883601A (zh) * 2009-12-02 2013-01-16 阿达玛斯医药公司 金刚烷胺组合物及其使用方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5221536A (en) 1990-05-07 1993-06-22 Alza Corporation Dosage form indicated for the management of abnormal posture, tremor and involuntary movement
US5358721A (en) 1992-12-04 1994-10-25 Alza Corporation Antiviral therapy
AUPN605795A0 (en) 1995-10-19 1995-11-09 F.H. Faulding & Co. Limited Analgesic pharmaceutical composition
WO2006053067A2 (en) * 2004-11-09 2006-05-18 Prestwick Pharmaceuticals, Inc. Combination of amantadine and a tetrabenazine compound for treating hyperkinetic disorders
US7619007B2 (en) 2004-11-23 2009-11-17 Adamas Pharmaceuticals, Inc. Method and composition for administering an NMDA receptor antagonist to a subject
US8389578B2 (en) 2004-11-24 2013-03-05 Adamas Pharmaceuticals, Inc Composition and method for treating neurological disease
US8574626B2 (en) 2004-12-03 2013-11-05 Osmotica Kereskedelmi és Szolgáltató KFT Osmotic device containing amantadine and an osmotic salt
US20080279819A1 (en) * 2005-02-15 2008-11-13 Adamas Pharmaceuticals, Inc. Combinations Therapy for Treatment of Demyelinating Conditions
EP1874282B1 (en) 2005-04-06 2010-09-15 Adamas Pharmaceuticals, Inc. Methods and compositions for treatment of cns disorders
US7981930B2 (en) 2007-03-13 2011-07-19 Adamas Pharmaceuticals, Inc. Compositions and kits for treating influenza
WO2014093475A1 (en) * 2012-12-11 2014-06-19 Acorda Therapeutics, Inc. Methods for treating parkinson's disease using aminopyridines
WO2014204933A1 (en) * 2013-06-17 2014-12-24 Adamas Pharmaceuticals, Inc. Amantadine compositions and methods of use

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102883601A (zh) * 2009-12-02 2013-01-16 阿达玛斯医药公司 金刚烷胺组合物及其使用方法

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Intravenous Amantadine for Freezing of Gait Resistant to Dopaminergic Therapy: A Randomized, Double-Blind,Placebo-Controlled, Cross-Over Clinical Trial;Kim et al.;《PLos ONE》;20121119;第7卷(第11期);摘要、第2页左栏第3段、第5页左栏第5段 *
Modulation of Neurological Deficits and Expression of Glutamate Receptors during Experimental Autoimmune Encephalomyelitis after Treatment with Selected Antagonists of Glutamate Receptors;Sulkowski et al.;《BioMed Research International》;20131231;第1页左栏第1段、第2页左栏第4段及右栏第2段、第3页右栏第3段-第4页左栏第1段 *

Also Published As

Publication number Publication date
SI3215132T1 (sl) 2021-11-30
EP3215132A4 (en) 2018-07-11
CN107205950A (zh) 2017-09-26
EP3215132B1 (en) 2021-01-27
JP6735020B2 (ja) 2020-08-05
EP3215132A1 (en) 2017-09-13
CA2966195A1 (en) 2016-05-12
MX376782B (es) 2025-03-07
AU2015343199A1 (en) 2017-05-18
AU2015343199B2 (en) 2021-04-08
WO2016073510A1 (en) 2016-05-12
US20160228388A1 (en) 2016-08-11
EP3909569A1 (en) 2021-11-17
PT3215132T (pt) 2021-05-07
HUE055779T2 (hu) 2021-12-28
JP2017533211A (ja) 2017-11-09
MX2017005578A (es) 2018-01-11
PL3215132T3 (pl) 2021-10-11
BR112017009289A2 (pt) 2017-12-19
CA2966195C (en) 2024-04-30
ES2865278T3 (es) 2021-10-15

Similar Documents

Publication Publication Date Title
CN107205950B (zh) 金刚烷胺组合物的施用方法
KR101752014B1 (ko) 고용량 및 저용량 약물들의 조합을 포함하는 구강붕해정 조성물
CN101378736B (zh) 用于口服给药的多微粒药物剂型
US11903908B2 (en) Methods of administering amantadine
JP5687185B2 (ja) 多粒子系を含む二段階の放出プロフィールを有する固形経口剤
WO2011013082A1 (en) Multi-layered, multiple unit pharmaceutical compositions
JP2017532363A (ja) 特に注意欠陥障害の治療のための方法および組成物
US8747895B2 (en) Orally disintegrating tablets of atomoxetine
WO2014028878A1 (en) Pharmaceutical compositions of memantine
WO2004056336A2 (en) Controlled release, multiple unit drug delivery systems
CN1161112C (zh) 含氯雷他定和伪麻黄碱的药物胶囊组合物
JP6902043B2 (ja) フマル酸ジメチルを含む医薬ビーズ製剤
EP3672581A1 (en) Amantadine compositions, preparations thereof, and methods of use
WO2011082426A1 (en) Controlled release compositions comprising meclizine or related piperazine derivatives
JP7714473B2 (ja) ピリミジニルアミノピラゾール化合物の調節放出製剤および処置方法
JP5919173B2 (ja) 徐放性塩酸アンブロキソール口腔内崩壊錠
CN121129799A (zh) 一种多重释放的缓控释组合物制剂及其制备方法和用途
US20180161281A1 (en) Extended release pharmaceutical composition of mixed amphetamines
EP2736496A1 (en) Pharmaceutical composition containing an antimuscarinic agent and method for the preparation thereof
HK1243939B (en) Amantadine for improving gait in multiple sclerosis
HK1243939A1 (en) Amantadine for improving gait in multiple sclerosis

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right
TA01 Transfer of patent application right

Effective date of registration: 20191115

Address after: California, USA

Applicant after: Adamas Pharmaceutical Co., Ltd.

Address before: California, USA

Applicant before: Adamas Pharmaceuticals, Inc.

GR01 Patent grant
GR01 Patent grant